Jade Biosciences, Inc. (JBIO)

NASDAQ: JBIO · Real-Time Price · USD
7.55
-0.07 (-0.92%)
Sep 3, 2025, 4:00 PM - Market closed
-0.92%
Market Cap246.33M
Revenue (ttm)n/a
Net Income (ttm)-93.96M
Shares Out 32.63M
EPS (ttm)-18.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume50,135
Open7.56
Previous Close7.62
Day's Range7.43 - 7.98
52-Week Range1.83 - 13.50
Betan/a
AnalystsStrong Buy
Price Target16.00 (+111.92%)
Earnings DateAug 13, 2025

About JBIO

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2024
Employees 30
Stock Exchange NASDAQ
Ticker Symbol JBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for JBIO stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 111.92% from the latest price.

Price Target
$16.0
(111.92% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic ...

2 days ago - GlobeNewsWire

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

10 days ago - GlobeNewsWire

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy...

21 days ago - GlobeNewsWire

Jade Biosciences to Participate in Two Upcoming Investor Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies ...

2 months ago - GlobeNewsWire

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

2 months ago - GlobeNewsWire

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 sh...

3 months ago - GlobeNewsWire

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

3 months ago - GlobeNewsWire

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to ent...

4 months ago - GlobeNewsWire

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...

4 months ago - GlobeNewsWire